Takeda Pharmaceutical Company Limited Additional Liabilities Contingent Liabilities Recognised In Business Combination
Takeda Pharmaceutical Company Limited (TAK) reported Additional Liabilities Contingent Liabilities Recognised In Business Combination of JPY 52.05 billion for the 12-month period ending 2019-03-31, per its 20-F filed 2019-06-27.
Discontinued › Notes
ifrs-full:AdditionalLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination · last filed 2019-06-27
| Period end | Additional Liabilities Contingent Liabilities Recognised In Business Combination 12 month |
|---|---|
| 2019-03-31 | 52.05B JPY 20-F · filed 2019-06-27 |
| 2018-03-31 | 3.16B JPY 20-F · filed 2019-06-27 |